WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company…
MORRISTOWN, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE)…
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models…
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline…
YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a…
Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022…
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a…
VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) — Agra Ventures Ltd. (“AGRA” or the…
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary…
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have…
LAKE FOREST, Ill., Feb. 23, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT),…
ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company…
CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a…
– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic…
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical…
NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a…
– Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND® (mitapivat) in Sickle Cell…
Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023…